Crescent Biopharma (NASDAQ:CBIO) Price Target Raised to $40.00

Crescent Biopharma (NASDAQ:CBIO – Free Report) had its price target hoisted by HC Wainwright from $36.00 to $40.00 in a research report sent to investors on Friday,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Several other research firms have also recently commented on CBIO. UBS Group reaffirmed a “buy” rating and set a $36.00 price objective on shares of Crescent Biopharma in a research report on Monday, October 19th. TD Cowen raised Crescent Biopharma to a “strong-buy” rating in a research report on Monday, August 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Crescent Biopharma in a report on Wednesday, November 4th. Finally, Wedbush reissued an “outperform” rating and set a $27.00 price objective on shares of Crescent Biopharma in a report on Monday, September 14th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $33.17.

Get Our Latest Report on Crescent Biopharma

Crescent Biopharma Stock Performance

Crescent Biopharma stock opened at $14.15 on Friday. The stock has a market cap of $525.59 million, a price-to-earnings ratio of -2.23 and a beta of 1.40. The stock’s 50 day simple moving average is $14.80 and its two-hundred day simple moving average is $15.88. Crescent Biopharma has a fifty-two week low of $8.72 and a fifty-two week high of $27.41.

Crescent Biopharma (NASDAQ:CBIO – Get Free Report) last released its earnings results on Thursday, November 12th. The biopharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.20). The firm had revenue of $3.12 million for the quarter, compared to analysts’ expectations of $0.62 million. On average, analysts predict that Crescent Biopharma will post -2.93 earnings per share for the current year.

Insider Transactions at Crescent Biopharma

In other news, CEO Joshua T. Brumm sold 7,837 shares of the stock in a transaction that occurred on Friday, September 18th. The shares were sold at an average price of $16.71, for a total value of $130,956.27. Following the transaction, the chief executive officer owned 271,765 shares in the company, valued at $4,541,193.15. This represents a 2.80% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Jonathan McNeill sold 3,839 shares of the firm’s stock in a transaction that occurred on Friday, September 18th. The stock was sold at an average price of $16.71, for a total transaction of $64,149.69. Following the completion of the transaction, the chief operating officer directly owned 134,588 shares in the company, valued at approximately $2,248,965.48. The trade was a 2.77% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 16,726 shares of company stock valued at $285,501. Corporate insiders own 24.84% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. State Street Corp grew its position in shares of Crescent Biopharma by 33.6% during the 3rd quarter. State Street Corp now owns 843,070 shares of the biopharmaceutical company’s stock valued at $12,300,000 after acquiring an additional 211,896 shares during the period. ACT Capital Partners L.P. purchased a new stake in shares of Crescent Biopharma in the 3rd quarter worth $168,000. Simplex Trading LLC purchased a new stake in shares of Crescent Biopharma in the 3rd quarter worth $50,000. Opaleye Management Inc. increased its stake in shares of Crescent Biopharma by 0.5% in the 2nd quarter. Opaleye Management Inc. now owns 1,319,351 shares of the biopharmaceutical company’s stock worth $23,748,000 after purchasing an additional 6,736 shares in the last quarter. Finally, Squarepoint Ops LLC purchased a new position in Crescent Biopharma during the second quarter valued at $435,000. 75.19% of the stock is currently owned by institutional investors.

More Crescent Biopharma News

Investors following CBIO have been watching these news items:

  • Positive Sentiment: HC Wainwright raised its price target from $36 to $40 and maintained a “buy” rating, signaling stronger analyst optimism. HC Wainwright recommendations
  • Neutral Sentiment: Piper Sandler lowered its target from $35 to $32 but kept an “overweight” rating, reflecting a reduced valuation outlook while remaining positive on the shares. Piper Sandler recommendations
  • Negative Sentiment: Third-quarter EPS was a loss of $0.90, worse than analysts’ expected loss of $0.70. Revenue of $3.12 million exceeded estimates, but net loss widened to $37.7 million from $24.6 million a year earlier as research and development spending increased. Third-quarter results and business highlights

About Crescent Biopharma

(Get Free Report)

Crescent Biopharma is a clinical-stage biotechnology company focused on developing medicines for cancer. Its research centers on antibody-based treatments, including therapies designed to target tumor cells and support the body’s immune response. The company’s work is directed toward advancing oncology drug candidates through clinical development. Its pipeline and programs may change as research progresses, and its products are investigational rather than established treatments. Crescent Biopharma is focused on developing its therapies for cancer patients; detailed information about its geographic operations and leadership is not included here.

Further Reading

Analyst Recommendations for Crescent Biopharma (NASDAQ:CBIO)

Receive News & Ratings for Crescent Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crescent Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.